Glaukos Corporation’s (GKOS Quick QuoteGKOS - Free Report) growth prospects are supported by the continued expansion of interventional glaucoma, growing clinical and commercial synergies between iDose TR and iStent infinite, and the potential for long-term operating leverage. However, physician workflow challenges, infrastructure constraints and margin pressure remain key risks.

Shares of this Zacks Rank #3 (Hold) company have gained 7.8% so far this year against the industry’s 16.7% decline. The S&P 500 Index has increased 10.2% in the same time frame.

Glaukos, with a market capitalization of $6.67 billion, is a leading ophthalmic medical technology and pharmaceutical company. The company has a trailing four-quarter average earnings surprise of 15.29%.

Image Source: Zacks Investment Research

Positive Factors Driving Prospects

iDose TR Is Rapidly Becoming a Transformational Growth Engine: Glaukos’ strongest growth catalyst remains iDose TR, which generated approximately $54 million in first-quarter revenue and helped drive U.S. glaucoma sales growth of 58% year over year. The product is benefiting from expanding physician adoption, increasing reimbursement coverage, growing utilization among trained surgeons and a rising body of clinical evidence.

Management highlighted that growth is broadening beyond early-adopter Medicare Administrative Contractor regions, with newer territories such as NGS and Palmetto beginning to contribute meaningfully. The gradual shift toward interventional glaucoma treatment creates a substantial market opportunity, particularly as iDose increasingly becomes integrated into standard care pathways for chronic glaucoma management. This expanding reimbursement and utilization profile significantly strengthens the product’s long-term revenue visibility.

Epioxa Launch Opens a Potentially Massive Market Opportunity: The commercial launch of Epioxa could represent Glaukos’ next major growth platform. Management views the product as a transformative advancement in keratoconus treatment because it eliminates the need for epithelial removal while improving patient experience and recovery. More importantly, Glaukos believes keratoconus remains dramatically underdiagnosed and undertreated.

While only about 18,000-20,000 eyes historically received treatment annually, management estimates that 50,000-100,000 eyes per year could ultimately qualify for therapy. Early launch indicators appear encouraging, with treatment access already established for over 100 million covered commercial lives and a site-of-care network covering approximately 65% of the U.S. population, potentially expanding to 95%. If adoption accelerates as expected, Epioxa could become a billion-dollar franchise over time.

Diversified Ophthalmology Portfolio: Unlike many emerging medtech companies that rely heavily on a single growth driver, Glaukos is building a diversified ophthalmology platform across glaucoma, corneal health and future retinal opportunities. The first-quarter results demonstrated strength across all major franchises, with consolidated revenue increasing 41% year over year to a record $150.6 million.

International glaucoma sales rose 23%, while corneal health sales increased 15% despite being in the middle of the Photrexa-to-Epioxa transition. This diversification reduces earnings volatility and creates multiple pathways for growth. The company maintains a pipeline of 13 disclosed development programs, including iDose TREX, PRESERFLO MicroShunt and iLution, which could provide additional commercial catalysts over the next several years.

Key Challenges

Epioxa Commercialization Faces Reimbursement Friction: Despite management’s enthusiasm regarding Epioxa, the launch remains in its earliest stages and faces meaningful reimbursement hurdles. The product is currently operating under a miscellaneous J-code until a permanent product-specific J-code becomes effective in July 2026. During this interim period, claims require individualized adjudication, creating administrative complexity and potentially slowing physician adoption.

Management acknowledged that patient access, prior authorizations and reimbursement workflows remain critical areas of focus. While early indicators are positive, commercialization success depends heavily on payer adoption, provider education and specialty pharmacy execution. Any delays in reimbursement standardization or slower-than-expected policy updates could materially delay the revenue ramp investors currently expect from Epioxa.

International Glaucoma Growth Faces Headwinds: Although international glaucoma delivered strong first-quarter performance, management cautioned that growth is likely to decelerate during the remainder of 2026. The company expects increasing competitive product trialing activity in several major international markets, which could pressure market share and pricing dynamics.

Favorable foreign exchange conditions that benefited first-quarter results are expected to diminish as the year progresses. Management specifically guided toward only high-single-digit growth in international glaucoma for the remainder of the year despite the strong start. This suggests that sustaining current growth rates may become increasingly difficult as competitive intensity rises and currency benefits fade, potentially limiting the segment’s contribution to overall corporate growth.

Core U.S. Glaucoma Business Remains Vulnerable: While iDose TR continues to outperform, the underlying non-iDose glaucoma business remains relatively mature and has yet to demonstrate sustained growth. Management continues to model essentially flat performance for the core U.S. glaucoma franchise despite two quarters of stabilization.

Executives acknowledged that recent results may have benefited from temporary competitive supply disruptions, making it difficult to determine whether recent improvements represent a durable trend. If the traditional glaucoma business returns to stagnation or decline, Glaukos could become increasingly dependent on iDose for growth. Such concentration would elevate execution risk, particularly if reimbursement, adoption or competitive dynamics surrounding iDose change unexpectedly.

Glaukos Corporation Price

Glaukos Corporation price | Glaukos Corporation Quote

Estimate Trend

The Zacks Consensus Estimate for 2026 revenues is pegged at $627.6 million, indicating a 23.7% improvement from the previous year’s level.

The consensus mark for loss per share is pinned at 57 cents, indicating a 36.7% improvement from the year-ago reported number. The consensus estimate for loss per share has remained stable in the past 30 days.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Globus Medical (GMED Quick QuoteGMED - Free Report) , Pacific Biosciences of California (PACB Quick QuotePACB - Free Report) and Biodesix (BDSX Quick QuoteBDSX - Free Report) .

Globus Medical, sporting a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.8% appreciation. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.

Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%.

PACB’s earnings are estimated to improve at a rate of 22.6% compared with the industry’s 13.7% growth in 2026. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.

Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.

BDSX has an estimated earnings growth rate of 40.47% for 2026 compared with the industry’s 13.7% return. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.